BIONTECH SE (BNTX): Price and Financial Metrics


1.05 (+1.10%)

POWR Rating

Component Grades













Add BNTX to Watchlist
Sign Up

Industry: Biotech


of 488

in industry

BNTX Stock Summary

  • BioNTech SE's stock had its IPO on October 10, 2019, making it an older stock than merely 1.22% of US equities in our set.
  • BNTX's price/sales ratio is 178.84; that's higher than the P/S ratio of 97.6% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, BioNTech SE is reporting a growth rate of 292.66%; that's higher than 94.82% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to BioNTech SE are ENTA, MORF, ANAB, CARA, and RCUS.
  • BNTX's SEC filings can be seen here. And to visit BioNTech SE's official web site, go to

BNTX Stock Price Chart Interactive Chart >

Price chart for BNTX

BNTX Price/Volume Stats

Current price $96.20 52-week high $131.00
Prev. close $95.15 52-week low $28.00
Day low $91.22 Volume 1,693,600
Day high $96.84 Avg. volume 2,170,305
50-day MA $105.83 Dividend yield N/A
200-day MA $85.23 Market Cap 23.16B


BioNTech SE focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches. The firm develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products. It offers drug discovery services for therapeutic areas including infectious diseases, allergies and autoimmune disorders.

BNTX Latest News Stream

Event/Time News Detail
Loading, please wait...

BNTX Latest Social Stream

Loading social stream, please wait...

View Full BNTX Social Stream

Latest BNTX News From Around the Web

Below are the latest news stories about BioNTech SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.

It’s a ‘split field’ in Texas over lifted mask mandate: Fort Worth Mayor

Betsy Price, Fort Worth Mayor, joins Yahoo Finance’s Kristin Myers to discuss Texas lifting its mask mandates and reopening businesses.

Yahoo | March 4, 2021

Biotech current stock performance is ‘actually pretty rational’: analyst

Yahoo Finance’s Julie Hyman, Brian Sozzi, and Myles Uldand discuss expectations in the health care sector with Oppenheimer Analyst Hartaj Singh.

Yahoo | March 4, 2021

Doctor: Health care workers are ‘frustrated and concerned’ over lifting of virus mandates

Dr. Heather Yeo, SurvivorNet Medical Advisor & Associate Professor of Surgery and Associate Professor of Population Health Sciences at New York Presbyterian Weill Cornell Medicine, joins Yahoo Finance’s Kristin Myers to discuss the latest coronavirus updates.

Yahoo | March 3, 2021

Novavax Under Pressure As It Guides To Vaccine Data; Is NVAX Stock A Buy?

Novavax said in January its coronavirus vaccine was 89.3% effective in a Phase 3 test. It's also effective against variants. It's now seeking authorization. Is NVAX stock a buy?

Yahoo | March 3, 2021

EU regulator not budging on vaccine dosage as states scramble for shots

The European Union drug regulator does not see enough evidence yet to recommend changes to the dosage regime for COVID-19 vaccines, despite pressure from EU states after positive data on the level of protection of a single shot. EU nations' vaccination plans are lagging behind the United States and former EU member Britain, a delay that has prompted some countries to push for new approaches, including on the administration of vaccines. For the Pfizer-BioNTech vaccine, London recommends the booster should be given after 12 weeks, whereas the guidance from the European Medicines Agency (EMA) follows the companies' recommendations of a second dose after three weeks.

Yahoo | March 3, 2021

Read More 'BNTX' Stories Here

BNTX Price Returns

1-mo -18.17%
3-mo -19.83%
6-mo N/A
1-year 152.56%
3-year N/A
5-year N/A
YTD 18.01%
2020 140.61%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8822 seconds.